Chief Medical Officer / Chief Medical Officeress

About SJP Biotec GmbH

SJP Biotec GmbH is a clinical-stage precision oncology company at the forefront of developing a first-in-class Selective Translation Regulatory Inhibitor (STRI) platform. Founded in 2024, we are dedicated to overcoming treatment resistance in refractory cancers, particularly those that are RAS-driven, hormone-receptor-positive, and immune-refractory. Our innovative pipeline of small molecules is developed in-house and is poised to advance into regulatory-grade trials.

Supported by a distinguished Scientific Advisory Board comprised of leading experts in RAS and breast cancer biology, as well as immuno-oncology, SJP has forged clinical partnerships with top-tier medical centers worldwide, including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill, among others.

The Opportunity

We invite you to join our dynamic and innovative biotech company at a pivotal moment in our development. As the Chief Medical Officer / Senior Vice President of Clinical Development, you will be the most senior clinical leader in the organization. You will be responsible for designing and implementing a multi-indication clinical development strategy in one of the most exciting areas of oncology drug development: RAS/eIF4A/translation-pathway inhibition.

Key Responsibilities

• Translate and deliver critical directives from the board and senior management while serving as the clinical face of the company.
• Lead and manage all clinical development activities across the SJP portfolio.
• Design Phase 2 and 3 clinical protocols and oversee CTA/IND submissions to BfArM, FDA, and EMA.
• Develop and implement biomarker-driven patient selection strategies.
• Build and maintain relationships with leading academic and clinical sites across Germany, the EU, and the US.
• Oversee Investigator Initiated Trials and partnerships, providing scientific leadership as required.
• Lead regulatory strategy, including Fast Track Designation, Breakthrough Therapy Designation, and accelerated approval pathways.
• Support pharmaceutical partnering activities by preparing clinical data packages and responding to due diligence requests.
• Contribute to the growth of the clinical development and operations function, including the recruitment of CRAs, medical monitors, and data management staff.
• Present clinical data at major oncology congresses and engage with key opinion leaders.
• Work with potential investors and financial institutions to secure capital when necessary.

Candidate Profile

Essential Qualifications

• MD with a specialization in medical oncology and hematology.
• 10+ years of experience in oncology clinical development within pharma, biotech, or CRO settings, with hands-on clinical trial leadership.
• Proven track record of successful IND/CTA submissions and leadership in interactions with FDA and/or EMA.
• Experience with biomarker-driven trial design and companion diagnostic development.
• Expertise in breast cancer, NSCLC, and KRAS-mutant tumor biology.
• Strong understanding of the competitive treatment landscape in clinical oncology.
• Proven ability to manage investigator-initiated trials and academic site partnerships.
• Robust scientific publication and/or congress presentation record in clinical oncology.
• Excellent presentation and teamwork skills, leading a team of experts in their respective fields.

Highly Desired (But Not Required)

• Experience with RAS/KRAS biology, MAPK pathway inhibitors, or translation-pathway therapeutics.
• PhD in a related area of cancer biology.
• Experience with basket trial design and multi-cohort oncology studies.
• Background in immuno-oncology combinations, particularly in checkpoint inhibitor resistance.
• Prior involvement in pharma partnering or licensing due diligence from the biotech perspective.
• Knowledge of German regulatory frameworks alongside international GCP/ICH guidelines.
• Established professional network at leading cancer centers.

Apply online using the form below. Only applications matching the job profile will be considered.